vs

Side-by-side financial comparison of CITIZENS FINANCIAL SERVICES INC (CZFS) and NEKTAR THERAPEUTICS (NKTR). Click either name above to swap in a different company.

CITIZENS FINANCIAL SERVICES INC is the larger business by last-quarter revenue ($29.6M vs $21.8M, roughly 1.4× NEKTAR THERAPEUTICS). CITIZENS FINANCIAL SERVICES INC runs the higher net margin — 35.4% vs -165.4%, a 200.9% gap on every dollar of revenue. On growth, CITIZENS FINANCIAL SERVICES INC posted the faster year-over-year revenue change (13.0% vs -25.3%). CITIZENS FINANCIAL SERVICES INC produced more free cash flow last quarter ($35.2M vs $-65.0M). Over the past eight quarters, CITIZENS FINANCIAL SERVICES INC's revenue compounded faster (6.9% CAGR vs 0.4%).

Citizens Financial Group, Inc. is an American bank holding company, headquartered in Providence, Rhode Island. The company owns the bank Citizens Bank, N.A., which operates in the U.S. states of Connecticut, Delaware, Florida, Maryland, Massachusetts, Michigan, New Hampshire, New Jersey, New York, Ohio, Pennsylvania, Rhode Island, Vermont, and Virginia, as well as Washington, DC.

Nektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances, which improves drug characteristics like retention and solubility. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, e...

CZFS vs NKTR — Head-to-Head

Bigger by revenue
CZFS
CZFS
1.4× larger
CZFS
$29.6M
$21.8M
NKTR
Growing faster (revenue YoY)
CZFS
CZFS
+38.2% gap
CZFS
13.0%
-25.3%
NKTR
Higher net margin
CZFS
CZFS
200.9% more per $
CZFS
35.4%
-165.4%
NKTR
More free cash flow
CZFS
CZFS
$100.2M more FCF
CZFS
$35.2M
$-65.0M
NKTR
Faster 2-yr revenue CAGR
CZFS
CZFS
Annualised
CZFS
6.9%
0.4%
NKTR

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CZFS
CZFS
NKTR
NKTR
Revenue
$29.6M
$21.8M
Net Profit
$10.5M
$-36.1M
Gross Margin
Operating Margin
44.2%
-126.9%
Net Margin
35.4%
-165.4%
Revenue YoY
13.0%
-25.3%
Net Profit YoY
31.3%
-596.9%
EPS (diluted)
$2.17
$-4.67

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CZFS
CZFS
NKTR
NKTR
Q4 25
$29.6M
$21.8M
Q3 25
$29.0M
$11.8M
Q2 25
$27.3M
$11.2M
Q1 25
$26.4M
$10.5M
Q4 24
$26.2M
$29.2M
Q3 24
$25.1M
$24.1M
Q2 24
$24.6M
$23.5M
Q1 24
$25.9M
$21.6M
Net Profit
CZFS
CZFS
NKTR
NKTR
Q4 25
$10.5M
$-36.1M
Q3 25
$10.0M
$-35.5M
Q2 25
$8.5M
$-41.6M
Q1 25
$7.6M
$-50.9M
Q4 24
$8.0M
$7.3M
Q3 24
$7.5M
$-37.1M
Q2 24
$5.3M
$-52.4M
Q1 24
$7.0M
$-36.8M
Gross Margin
CZFS
CZFS
NKTR
NKTR
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
72.7%
Q3 24
81.6%
Q2 24
58.5%
Q1 24
60.6%
Operating Margin
CZFS
CZFS
NKTR
NKTR
Q4 25
44.2%
-126.9%
Q3 25
42.6%
-268.6%
Q2 25
38.1%
-324.2%
Q1 25
35.5%
-425.8%
Q4 24
37.2%
49.2%
Q3 24
36.9%
-142.4%
Q2 24
25.9%
-211.9%
Q1 24
32.8%
-163.7%
Net Margin
CZFS
CZFS
NKTR
NKTR
Q4 25
35.4%
-165.4%
Q3 25
34.5%
-301.3%
Q2 25
31.0%
-372.2%
Q1 25
28.8%
-486.4%
Q4 24
30.5%
24.9%
Q3 24
30.0%
-153.6%
Q2 24
21.4%
-222.9%
Q1 24
27.1%
-170.1%
EPS (diluted)
CZFS
CZFS
NKTR
NKTR
Q4 25
$2.17
$-4.67
Q3 25
$2.09
$-1.87
Q2 25
$1.76
$-2.95
Q1 25
$1.60
$-0.24
Q4 24
$1.64
$-2.07
Q3 24
$1.57
$-2.66
Q2 24
$1.10
$-3.76
Q1 24
$1.48
$-0.19

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CZFS
CZFS
NKTR
NKTR
Cash + ST InvestmentsLiquidity on hand
$34.3M
$15.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$338.1M
$89.8M
Total Assets
$3.1B
$280.4M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CZFS
CZFS
NKTR
NKTR
Q4 25
$34.3M
$15.1M
Q3 25
$31.1M
$41.0M
Q2 25
$49.5M
$43.0M
Q1 25
$36.8M
$38.9M
Q4 24
$42.2M
$44.3M
Q3 24
$36.8M
$30.1M
Q2 24
$38.4M
$27.9M
Q1 24
$29.6M
$48.6M
Stockholders' Equity
CZFS
CZFS
NKTR
NKTR
Q4 25
$338.1M
$89.8M
Q3 25
$327.7M
$85.1M
Q2 25
$313.7M
$-24.2M
Q1 25
$308.3M
$13.7M
Q4 24
$299.7M
$60.7M
Q3 24
$298.7M
$48.9M
Q2 24
$286.5M
$79.7M
Q1 24
$282.7M
$126.7M
Total Assets
CZFS
CZFS
NKTR
NKTR
Q4 25
$3.1B
$280.4M
Q3 25
$3.1B
$301.3M
Q2 25
$3.0B
$207.5M
Q1 25
$3.0B
$256.2M
Q4 24
$3.0B
$303.9M
Q3 24
$3.0B
$308.0M
Q2 24
$2.9B
$343.3M
Q1 24
$2.9B
$396.0M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CZFS
CZFS
NKTR
NKTR
Operating Cash FlowLast quarter
$36.5M
$-65.0M
Free Cash FlowOCF − Capex
$35.2M
$-65.0M
FCF MarginFCF / Revenue
119.0%
-298.0%
Capex IntensityCapex / Revenue
4.4%
0.1%
Cash ConversionOCF / Net Profit
3.49×
TTM Free Cash FlowTrailing 4 quarters
$53.8M
$-208.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CZFS
CZFS
NKTR
NKTR
Q4 25
$36.5M
$-65.0M
Q3 25
$2.9M
$-48.8M
Q2 25
$6.0M
$-45.7M
Q1 25
$10.9M
$-49.1M
Q4 24
$33.2M
$-46.2M
Q3 24
$6.2M
$-43.9M
Q2 24
$3.0M
$-37.7M
Q1 24
$13.5M
$-47.9M
Free Cash Flow
CZFS
CZFS
NKTR
NKTR
Q4 25
$35.2M
$-65.0M
Q3 25
$2.7M
$-48.9M
Q2 25
$5.5M
$-45.8M
Q1 25
$10.4M
$-49.1M
Q4 24
$31.9M
$-46.6M
Q3 24
$5.6M
$-44.6M
Q2 24
$2.9M
$-37.9M
Q1 24
$13.4M
$-48.0M
FCF Margin
CZFS
CZFS
NKTR
NKTR
Q4 25
119.0%
-298.0%
Q3 25
9.4%
-414.5%
Q2 25
20.1%
-409.6%
Q1 25
39.2%
-469.0%
Q4 24
121.6%
-159.9%
Q3 24
22.3%
-184.9%
Q2 24
11.8%
-161.3%
Q1 24
51.5%
-222.0%
Capex Intensity
CZFS
CZFS
NKTR
NKTR
Q4 25
4.4%
0.1%
Q3 25
0.5%
1.0%
Q2 25
1.8%
0.3%
Q1 25
2.2%
0.0%
Q4 24
5.0%
1.6%
Q3 24
2.5%
2.8%
Q2 24
0.5%
0.8%
Q1 24
0.4%
0.7%
Cash Conversion
CZFS
CZFS
NKTR
NKTR
Q4 25
3.49×
Q3 25
0.29×
Q2 25
0.71×
Q1 25
1.44×
Q4 24
4.16×
-6.36×
Q3 24
0.83×
Q2 24
0.57×
Q1 24
1.92×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons